Kailera falls after late-stage trial data for oral GLP-1 candidate
Seeking Alpha News (Tue, 7-Jul 11:41 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 7-Jul 10:40 AM ET)
Globe Newswire (Tue, 7-Jul 7:00 AM ET)
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Globe Newswire (Mon, 29-Jun 7:30 AM ET)
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Globe Newswire (Fri, 5-Jun 7:32 PM ET)
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Thu, 28-May 4:05 PM ET)
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Globe Newswire (Tue, 26-May 4:02 PM ET)
Globe Newswire (Wed, 13-May 7:30 AM ET)
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
PRNewswire (Wed, 22-Apr 5:40 AM ET)
Globe Newswire (Mon, 20-Apr 4:05 PM ET)
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Kailera Therapeutics trades on the NASDAQ stock market under the symbol KLRA.
As of July 7, 2026, KLRA stock price declined to $21.23 with 555,556 million shares trading.
KLRA has a market cap of $2.75 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that KLRA belongs to (by Net Assets): IWM, VTI, VB, IWO, VBR.
KLRA support price is $22.04 and resistance is $24.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KLRA shares will trade within this expected range on the day.
